Association of single-click radiomic classifier with response and prognosis in non-small cell lung cancers (NSCLC) treated with immune checkpoint inhibitors.

Authors

null

Amogh Hiremath

Picture Health, Cleveland, OH

Amogh Hiremath , Haojia Li , Allison Clement , Amit Gupta , Vamsidhar Velcheti , Anant Mababhushi , Nathaniel Braman

Organizations

Picture Health, Cleveland, OH, University Hospitals Cleveland Medical Center, Cleveland, OH, New York University, Laura and Isaac Perlmutter Cancer Center, New York, NY, Emory University and Georgia Institute of Technology, Atlanta, GA

Research Funding

Other
Industrial funding

Background: Radiomics has shown promise to non-invasively phenotype disease and address the limitations of extant biomarkers (e.g. PD for immune checkpoint inhibitors (ICI) in cancers, such as NSCLC. However, considerable barriers to the clinical adoption of these tools remain, such as their dependence on precise annotation of tumor extent by experienced clinical users. Here, we demonstrate a radiomic solution that requires only a single user mouse click within one or more target lesions on a baseline CT scan, to contour tumors in 3D and generate a patient-level radiomic prediction of response and outcome in ICI treated NSCLC patients. Methods: 1778 CT scans from 1261 patients were used to develop and validate an interactive, semi-automated tool for predicting ICI outcomes in NSCLC patients prior to therapy. A user click based deep learning contouring model was trained and validated on 1146 patients, then used to create annotations for radiomic analysis. A least absolute shrinkage and selection operator (LASSO) Cox proportional hazards model was utilized to select features associated with post-ICI overall survival (OS) and derive a radiomic risk score within a training cohort (n=74) that can separate patients into high and low risk groups. The model was tested on held out pre-treatment CTs of 41 ICI recipients from 2 institutions for association with OS, progression-free survival (PFS), and objective response (OR). Results: A total of 77 lesions were identified and segmented within the testing set. Average volume per lesion was 54.10 mL and per patient was 101.60 mL. OR was observed in 48.70% of patients. A threshold of -0.31 defining high and low radiomic risk groups was chosen based on optimal separation within the training set (HR=2.59 [95% 1.48~4.50], p=0.0009). Radiomic risk groups significantly stratified patients by OS (C-index=0.64, HR=3.03 [95% 1.15~8.02], p=0.03) and PFS (C-index=0.59, HR=3.20 [95% 1.13~9.10], p=0.03). Radiomic IO risk group was independently prognostic of clinical variables (Table 1) and further predicted ICI response with AUC=0.74 [95% 0.71-0.78]. Conclusions: From a single click in target lesions, our model was able to predict response and prognosis of ICI recipients from a baseline radiology scan. Additional multi-site validation and prospective evaluation will assess the value of the radiomics classifier as a decision support tool in the clinic.

VariablesHR [95% CI]p
Radiomic high risk4.82 [1.41~16.53]0.01
Gender (F vs. M)0.81 [0.27~2.45]0.71
Stage (per stage increase)2.62 [0.60~11.44]0.20
Smoking history0.68 [0.28~1.64]0.39
Histology0.88 [0.54~1.45]0.62

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Track

Lung Cancer

Sub Track

Local-Regional Non–Small Cell Lung Cancer

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 8574)

DOI

10.1200/JCO.2023.41.16_suppl.8574

Abstract #

8574

Poster Bd #

201

Abstract Disclosures